Macroscopic Examination of Surgical Specimen of Esophageal Squamous Cell Carcinoma

Lam, Alfred King‐Yin

doi:10.1007/978-1-0716-0377-2_4

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of neoadjuvant therapy may shrink the cancer or result in complete or nearcomplete response, with fibrosis detected macroscopically (Figure 1A) [17]. As a result, identification of the lesion macroscopically can be difficult.…”

Section: Neoadjuvant Therapymentioning

confidence: 99%

Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting

Lam¹,

Bourke²,

Chen³

et al. 2021

Human Pathology

Self Cite

View full text Add to dashboard Cite

Section: Neoadjuvant Therapymentioning

confidence: 99%

Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting

Lam¹,

Bourke²,

Chen³

et al. 2021

Human Pathology

Self Cite

View full text Add to dashboard Cite

“…Histological types and grades of selected ESCCs were assessed based on the current World Health Organization histological typing of esophageal tumors prior to analysis (24). Pathological staging was identified according to the current Cancer Staging Manual of the American Joint Committee on Cancer (25).…”

Section: Patients and Clinicopathological Parametersmentioning

confidence: 99%

Molecular Deregulation of EPAS1 in the Pathogenesis of Esophageal Squamous Cell Carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Endothelial PAS domain-containing protein 1 (EPAS1) is an angiogenic factor and its implications have been reported in many cancers but not in esophageal squamous cell carcinoma (ESCC). Herein, we aim to examine the genetic and molecular alterations, clinical implications, and functional roles of EPAS1 in ESCC. High-resolution melt-curve analysis and Sanger sequencing were used to detect mutations in EPAS1 sequence. EPAS1 DNA number changes and mRNA expressions were analyzed by polymerase chain reaction. in vitro functional assays were used to study the impact of EPAS1 on cellular behaviors. Overall, 7.5% (n = 6/80) of patients with ESCC had mutations in EPAS1, and eight novel variants (c.1084C>T, c.1099C>A, c.1145_1145delT, c.1093C>G, c.1121T>G, c.1137_1137delG, c.1135_1136insT, and c.1091_1092insT) were detected. Among these mutations, four were frameshift (V382Gfs * 12, A381Lfs * 13, K379Ifs * 6, and K364Nfs * 12) mutations and showed the potential of nonsense mediated mRNA decay (NMD) in computational analysis. The majority of patients showed molecular deregulation of EPAS1 [45% (n = 36/80) DNA amplification, 42.5% (n = 34/80) DNA deletion, as well as 53.7% (n = 43/80) high mRNA expression, 20% (n = 16/80) low mRNA expression]. These alterations of EPAS1 were associated with tumor location and T stages. Patients with stage III ESCC having EPAS1 DNA amplification had poorer survival rates in comparison to EPAS1 DNA deletion (p = 0.04). In addition, suppression of EPAS1 in ESCC cells showed reduced proliferation, wound healing, migration, and invasion in comparison to that of control cells. Thus, the molecular and functional studies implied that EPAS1 plays crucial roles in the pathogenesis of ESCC and has the potential to be used as a prognostic marker and as a therapeutic target.

show abstract

Macroscopic Examination of Surgical Specimen of Esophageal Squamous Cell Carcinoma

Cited by 2 publications

References 20 publications

Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting

Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting

Molecular Deregulation of EPAS1 in the Pathogenesis of Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About